Lepodisiran: A Novel Therapy to Reduce Lipoprotein(a)

Steven Nissen, MD, shares the findings from a late breaker he presented at ACC 2025.  Lepodisiran is a small interfering RNA that targets lipoprotein(a) levels, lowering a patient's risk for atherosclerosis and aortic stenosis. https://my.clevelandclinic.org/staff/1185-steven-nissen

Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.